MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from publicofferings$6,090K Proceeds from warrantinducement financing$4,136K Proceeds from exercise ofpre-funded warrants$2K Net cash provided byfinancing activities$9,480K Canceled cashflow$748K Net increase(decrease) in cash and...$5,215K Canceled cashflow$4,265K Repayment of principal onrelated party term notes...$375K Payment of financingcosts$344K Repayment of financinglease obligations$29K Stock-based compensation$529K Depreciation andamortization expense$427K Accrued expenses andother current...$264K Prepaid expenses andother current assets-$118K Change in fair value ofother liabilities and...$100K Net cash used inoperating activities-$4,238K Net cash used ininvesting activities-$27K Canceled cashflow$1,438K Net loss-$5,181K Purchases of machinery andequipment$27K Operating lease right ofuse liability-$304K Accounts payable-$191K
Cash Flow
source: myfinsight.com

Calidi Biotherapeutics, Inc. (CLDWW)

Calidi Biotherapeutics, Inc. (CLDWW)